This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $1080 | Check With Us |
500mg | $1600 | Check With Us |
1g | $2400 | Check With Us |
Cat #: V3174 CAS #: 1039455-84-9 Purity ≥ 98%
Description: COTI-2 is an orally available, 3rd generation small molecule activator of the mutant p53 protein (a tumor suppressor).
References: Duffy MJ, et al. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017 Sep;83:258-265.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 366.48 |
---|---|
Molecular Formula | C19H22N6S |
CAS No. | 1039455-84-9 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: >70 mg/mLr |
Water: < 1 mg/mLr | |
Ethanol: < 1 mg/mL | |
SMILES Code | S=C(N1CCN(C2=NC=CC=C2)CC1)N/N=C3CCCC4=C3N=CC=C4 |
Synonyms | COTI2; COTI-2; COTI 2 |
Protocol | In Vitro | COTI-2 efficiently inhibits the proliferation rate of all the tested cell lines following 72 h of treatment. COTI-2 is significantly effective at inhibiting tumor cell proliferation in all three cell lines (COLO-205, HCT-15, and SW620). Relatively low concentrations of COTI-2 are active against all human glioblastoma cell lines tested (U87-MG, SNB-19, SF-268, and SF-295). COTI-2 treatment of SHP-77 cells with approximate IC50 concentrations results in the induction of early apoptosis among 40 to 47% of total cells. |
---|---|---|
In Vivo | COTI-2 significantly inhibits tumor growth in the HT-29 human colorectal tumor xenografts at a dose of 10 mg/kg. In addition to reducing tumor volumes at specific times post-treatment, COTI-2 also delays the time required for tumors to reach specified volumes. COTI-2 also significantly inhibits tumor growth in the SHP-77 SCLC xenograft model at a dose as low as 3 mg/kg. COTI-2 treatment both reduces U87-MG tumor volumes at specific times post-treatment and lengthens the time required for U87-MG xenografts to grow in nude mice. Control tumors in mice treated with vehicle alone take only 5 days to reach an average volume of 828 mm3 while tumors in animals treated with COTI-2 take double that time (10 days) to reach a similar mean volume (857 mm3). COTI-2 treatment effectively inhibits OVCAR-3 xenograft growth regardless of the route of administration. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.7287 mL | 13.6433 mL | 27.2866 mL | 54.5732 mL |
5mM | 0.5457 mL | 2.7287 mL | 5.4573 mL | 10.9146 mL |
10mM | 0.2729 mL | 1.3643 mL | 2.7287 mL | 5.4573 mL |
20mM | 0.1364 mL | 0.6822 mL | 1.3643 mL | 2.7287 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.